A Multifactorial Model of T Cell Expansion and Durable Clinical Benefit in Response to a PD-L1 Inhibitor
M. D. Leiserson, V. Syrgkanis, A. Gilson, M. Dudik, S. Gillett, J. Chayes, C. Borgs, D. F. Bajorin, J. Rosenberg, S. Funt, A. Snyder, L. Mackey
This paper develops a multifactorial model to predict T cell expansion and clinical benefit from PD-L1 inhibitors using clinical, tumor, and circulating features, showing improved accuracy over single biomarkers.
bioRxiv · Apr 10, 2018Cancer Biology